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1. Introduction 
Percutaneous arterial catheterization and transluminal dilatation of stenotic vessels were 
first described by Charles T. Dotter and Melvin P. Judkins in their seminal paper published 
in 1964 (1). With the advent of contemporary coronary angioplasty and stenting techniques 
for patients with coronary artery disease (CAD) and acute coronary syndromes (ACS), the 
procedure has now been termed percutaneous coronary intervention (PCI). While PCI has 
done much in the modern era to improve patient outcomes in the face of acute myocardial 
infarction as well as in disabling cardiac angina, its benefits can still be limited by peri-
procedural complications such as acute vessel closure and stent thrombosis as well as 
conditions occurring after 30 days post-PCI, such as in-stent restenosis or late stent 
thrombosis. Additionally, catheter and wire associated thrombus formation can occur 
during PCI in the absence of adequate anticoagulation.  Excess anticoagulation on the other 
hand carries a risk of major gastrointestinal or intracranial bleeding as well as vascular 
access bleeding complications. Stent thrombosis is a rare, but serious complication of PCI 
and usually presents as death or ST-elevation myocardial infarction. Coronary stents are 
generally made of stainless steel or cobalt chromium alloys rendering them thrombogenic 
until they are completely covered by endothelial tissue.  The timing of complete 
endothelialization is variable and depends on whether the implanted stent is bare metal or 
drug-eluting, as well as which type of anti-proliferative drug the stent is coated with.  Stent 
thrombosis can be described based on its timing relative to stent placement and is associated 
with a number of different risk factors (Table 1).  Acute stent thrombosis occurs within 24 
hours of PCI and in one pooled analysis, approximately 80 percent of all bare metal stent 
(BMS) thromboses occurred within this acute period (2). Subacute stent thrombosis occurs 
up to 30 days after PCI and this time period encompasses the majority of all thrombotic 
events observed in both BMS and drug-eluting stents (DES) (3). Stent thrombosis after 30 
days and up to one year post-PCI is referred to as late stent thrombosis and seems to occur 
with equal frequency in BMS and DES, particularly in the absence or cessation of dual anti-
platelet therapy with aspirin or clopidogrel (4-5). Occurring even less commonly at greater 
than one year post-PCI, very late stent thrombosis appears to be associated with DES more 
than BMS and is thought to be related to delayed neo-intimal coverage as well as ongoing 
vessel inflammation (6). Current ACC/AHA guidelines make a number of 
recommendations regarding the concurrent use of antiplatelet, antithrombotic, and 
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thrombolytic pharmacotherapy during PCI to prevent such complications.  The goal of this 
chapter will be to describe different therapeutic agents available to clinicians during PCI and 
to summarize the most current guidelines regarding their use.  
2. Anti-platelet agents 
2.1 Aspirin 
Aspirin causes an irreversible inactivation of the cyclooxygenase-1 enzyme required for 
prostaglandin and thromboxane synthesis, which in turn diminishes platelet aggregation. 
The use of aspirin for secondary prevention has been shown to decrease overall mortality in 
patients with established CAD or a CAD equivalent such as diabetes (7-10). Meanwhile, the 
net benefit for its use in primary prevention is less certain and needs to be weighed against 
individual risk for major gastrointestinal or extra-cranial bleeding (11).  Extensive studies 
have also shown significant reductions in mortality and morbidity with the use of aspirin in 
unstable angina (UA) as well as in both non-ST-elevation myocardial infarction (NSTEMI) 
and ST-elevation myocardial infarction (STEMI). In one of the earliest trials from the Results 
of a Veterans Administration Cooperative Study, Lewis et al. reported a 51% reduction in 
incidence of death or acute MI as well as a 50% reduction in rates of nonfatal MI in patients 
with UA who received aspirin (12). These findings were reproduced in subsequent studies 
and helped to solidify the role for the use of aspirin in UA (13-14). The RISC trial evaluated 
the role of aspirin in both NSTEMI and UA patients and again demonstrated that aspirin 
was associated with a significant reduction in the combined endpoint of death and MI with 
differences persisting beyond one-year providing evidence for the long-term benefit of 
aspirin in NSTE-ACS (15). The landmark trial ISIS-2 then expanded the role of aspirin use to 
standard therapy in STEMI (16). ISIS-2 randomized 17,187 patients presenting with acute 
STEMI to streptokinase, aspirin, both therapies, or neither, and demonstrated an additive 
effect of aspirin to thrombolytic therapy. Currently, the ACC/AHA guidelines for the 
management of UA, NSTEMI and STEMI recommend immediate treatment with aspirin for 
all patients for indefinite duration (17).  The recommendations for the use of aspirin in PCI 
with stenting are derived from several early clinical trials in which treatment with high dose 
aspirin (650 mg to 990 mg/day) along with dipyridamole or ticlopidine in percutaneous 
transluminal coronary angioplasty (PTCA) was compared to placebo.  Patients who were 
treated with aspirin-based regimens uniformly had better outcomes with significant 
reductions in peri-procedural complications including abrupt vessel closure, dissection or 
MI (18-19). Pre-treatment with aspirin monotherapy was tested against aspirin plus 
dipyridamole and shown to have an independent beneficial effect (20). Subsequent studies 
comparing high-dose versus low-dose aspirin (1500 mg vs. 80 mg/day) prior to PTCA 
showed no difference in the incidence of MI or in the rate of major complications and 
restenosis (21). The most current ACC/AHA recommendations for the use of aspirin in PCI 
are that higher dose aspirin (300 mg to 325 mg) be given at least 2 hours before PCI as well 
as for at least 1 month after BMS implantation, 3 months after sirolimus-eluting stent 
implantation, and 6 months after paclitaxel-eluting stent implantation (17).    
2.2 Ticlopidine 
Thienopyridines block the adenosine diphosphate (ADP) receptor P2Y12 on platelet surfaces 
thereby decreasing platelet activation and aggregation (see section on platelet function 
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testing below). Ticlopidine was the first widely used thienopyridine that began to have an 
antiplatelet effect within 24 to 48 hours after its administration. The STAIG trial was one of 
the first multicenter trials to evaluate the role of thienopyridines, particularly ticlopidine, in 
ACS (22). 652 patients with UA were randomized within 48 hours of presentation to 
conventional medical therapy alone versus ticlopidine in addition to conventional 
treatment. Ticlopidine use was associated with a reduction in vascular mortality by 46.8% 
(4.8% vs. 8.9%) and MI by 53.2% (5.1% vs. 10.9%). Further randomized trials such as STARS, 
MATTIS, ISAR, and FANTASTIC compared antiplatelet therapy with ticlopidine and 
aspirin to conventional anticoagulant therapy with heparin or warfarin in PCI with bare 
metal stenting and demonstrated a clear reduction in stent thrombosis, death, MI, or 
emergent CABG (23-26). Ticlopidine use, however, has been associated with significant side 
effects including thrombocytopenia, neutropenia and thrombotic thrombocytopenic 
purpura-hemolytic uremic syndrome (TTP-HUS); thus it is crucial that biweekly monitoring 
of blood counts be performed for four months after initiation of ticlopidine (27-28).  
2.3 Clopidogrel 
Due to the unfavorable side effect profile of ticlopidine, interest began to develop in 
clopidogrel as a potential thienopyridine alternative. The efficacy of clopidogrel in the 
treatment of CAD had already been demonstrated in the CAPRIE trial in which clopidogrel 
use significantly reduced the combined endpoint of ischemic stroke, MI and vascular death 
in patients with atherosclerotic disease (29). Clopidogrel’s overall safety benefit as compared 
to ticlopidine was then convincingly demonstrated in the CLASSICS trial and a meta-
analysis later found that clopidogrel use was at least as efficacious as ticlopidine with fewer 
major adverse cardiac events (MACE) as well as a lower incidence of mortality (30-31).  
Based on these findings, clopidogrel replaced ticlopidine as the thienopyridine of choice in 
combination with aspirin as standard therapy after PCI. Several landmark trials then fully 
expanded the application of clopidogrel therapy to ACS and PCI. Investigators in the CURE 
trial found a 20% reduction in the primary combined endpoint of cardiovascular death, MI, 
or stroke (9.3% vs. 11.4%) in 12,562 patients with NSTE-ACS when treated with combined 
aspirin and clopidogrel as compared to aspirin alone (32). When the subset of patients 
undergoing PCI was analyzed separately in the PCI-CURE substudy, pre-treatment with 
clopidogrel plus aspirin prior to PCI led to both immediate and long-term benefits in 
reducing ischemic vascular events and death (33-34). The CREDO trial later confirmed the 
benefit of upstream clopidogrel therapy in more than 2,100 patients who were randomized 
to receive either clopidogrel at a 300 mg loading dose or placebo 3 to 24 hours before 
elective PCI, followed by 75 mg/day for 28 days in both groups and then either clopidogrel 
or placebo out to one year according to the original randomization (35). The results from 
CREDO also proved the benefits of long-term clopidogrel therapy by finding a 26.9% 
relative risk reduction in the combined end point of death, MI, or stroke at one year (8.5% 
vs. 11.5%, 95% CI 3.9-44.4). Two additional randomized trials, CLARITY-TIMI 28 and 
COMMIT/CCS-2, then demonstrated that clopidogrel therapy when added to aspirin  
also improved outcomes in patients with STEMI being treated with fibrinolytics and heparin 
(36-37).  
With the role of clopidogrel now clearly defined in all forms of ACS as well as PCI, the 
timing and dose of clopidogrel pre-treatment for PCI came under question.  In a pre-
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specified sub-group analysis, the PCI-CLARITY trial found that early treatment with 
clopidogrel (300 mg) led to significantly better outcomes in all time groups ranging from 
within 6 hours before PCI to as far as 96 hours ahead of PCI (38).  A substudy from CREDO, 
however, found that the benefit was only seen if clopidogrel (300 mg) was given 10 to 12 
hours before PCI and did not become significant unless given >15 hours prior to PCI, with a 
maximum effect seen at 24 hours (39). 
Since pre-treatment with clopidogrel for >15 hours prior to PCI is not always practical in 
situations of ACS or ad hoc decisions to stent at the time of diagnostic angiography, the 
issue was raised as to whether higher loading doses of clopidogrel could be beneficial by 
increasing the level of platelet inhibition or by decreasing the time required until its 
maximum antiplatelet effects were achieved. In an unselected cohort of over 1,000 patients, 
who were given a 600 mg dose of clopidogrel, in vitro studies found that maximum platelet 
inhibition was seen by two hours and additional testing showed that clopidogrel 600 mg 
dosing seemed to achieve more intense levels of peak platelet inhibition when compared 
with the conventional 300 mg dose (40-41). Several large studies then sought to evaluate 
whether these pharmacodynamic differences could translate into improved patient 
outcomes. The ARMYDA-2 trial randomized 255 patients with stable angina or NSTE-ACS 
to either 600 mg or 300 mg of clopidogrel given four to eight hours prior to PCI (42). By 30 
days, the composite endpoint of death, MI, or target vessel revascularization (TVR) occurred 
in only 4% of the 600 mg group as compared to 12% in the 300-mg group, a difference that 
was entirely driven by rates of peri-procedural MI (p <0.05). No differences were reported in 
the rates of major bleeding between the two groups. The benefit of a clopidogrel 600 mg 
loading dose was seen again in a subgroup analysis from the HORIZONS-AMI trial in 
which 3,602 patients with STEMI undergoing primary PCI were randomized to either 
bivalirudin or unfractionated heparin (UFH) plus a glycoprotein (GP) IIb/IIIa inhibitor (43). 
Clopidogrel loading doses of either 300 mg (1,153 patients) or 600 mg (2,158 patients) were 
chosen at the clinician’s discretion and after multivariable analysis, the 600 mg dose was 
found to be an independent predictor of lower rates of 30-day MACE without higher 
bleeding. The CURRENT-OASIS 7 trial then randomized over 25,000 patients with ACS 
(29.2% STEMI) who were referred for an invasive strategy and compared the regimen of 
double dose clopidogrel (600 mg loading dose followed by 150 mg daily for six days and 
then 75 mg daily thereafter) versus standard dose clopidogrel (300 mg loading dose 
followed by 75 mg daily) (44).  The investigators found that while there was no significant 
difference in the primary outcome of cardiovascular death, MI or stroke at 30 days (4.2% in 
the double dose group vs. 4.4% in the standard dose group; HR 0.94; 95% CI 0.83-1.06; p 
=0.30), double dose clopidogrel was associated with a significant reduction in the secondary 
outcome of stent thrombosis in the greater than 17,000 patients who underwent PCI (1.6% 
vs. 2.3%; HR 0.68; 95% CI 0.55-0.85; p=0.001). Notably, major bleeding occurred significantly 
more in the double dose group (2.5% vs. 2.0%; HR 1.24; 95% CI 1.05-1.46; p=0.01). Several 
subsequent smaller studies including ISAR-CHOICE, ALBION, and PREPAIR have 
attempted to look at whether even higher loading doses of clopidogrel (900 mg and 1200 
mg) might carry additional benefit when compared to the 600 mg and 300 mg doses (45-47).  
These studies found that while treatment with increasing doses of clopidogrel did in fact 
result in greater levels of platelet inhibition, clinical endpoints such as MACE and troponin 
release were not statistically different. At this point, larger prospective trials evaluating 
clinical outcomes are needed before clopidogrel loading doses above 600 mg can be justified. 
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With regards to timing of double-dose clopidogrel pre-treatment, the ISAR-REACT trial 
showed that among 2,159 patients undergoing PCI, a clopidogrel 600 mg loading dose could 
be given as early as as 2 hours prior to PCI without detrimental effects when compared to 
longer durations of pre-treatment (2 to 3 hours, 3 to 6 hours, 6 to 12 hours, > 12 hours) (48). 
Similarly, the PRAGUE-8 and ARMYDA-5 PRELOAD trials reported no differences in 
outcomes when clopidogrel 600 mg was given to patients with stable angina or NSTE-ACS 
either before (mean of 19 and 6 hours respectively) or immediately after diagnostic coronary 
angiography, but prior to PCI (49-50). 
The RELOAD and ARMYDA-4 RELOAD trials attempted to address the question of 
whether an additional loading dose of clopidogrel was required prior to PCI in stable and 
ACS patients who were already receiving chronic clopidogrel therapy (51-52). The trials 
found that although clopidogrel reloading produced significantly greater levels of platelet 
inhibition, there was no difference in the primary endpoint of MACE. A subgroup analysis, 
however, showed that when reloaded with clopidogrel 600 mg, there was a significant 
benefit in patients with ACS who underwent PCI. While there is not enough evidence to 
make definitive recommendations regarding this issue, it may be reasonable to reload 
patients receiving chronic clopidogrel therapy with clopidogrel 600 mg prior to PCI for ACS 
or if their risk for stent thrombosis is high.  
2.4 Prasugrel 
Despite the increasing use of higher doses of clopidogrel, there are still many cases of 
breakthrough thrombotic events in patients receiving standard dual antiplatelet therapy 
(32). Limitations of clopidogrel therapy are thought to be due to its delayed onset of action, 
modest platelet inhibition effects, and a wide range of inter-individual variability with 
regards to platelet responsiveness. Prasugrel is a third-generation thienopyridine and like 
clopidogrel, also requires biotransformation to its active metabolite before binding to P2Y12 
receptors and inhibiting platelet aggregation. In contrast to clopidogrel however, prasugrel 
has been shown to achieve greater levels of platelet inhibition more rapidly and more 
consistently among healthy individuals as well as in patients with CAD and those who are 
undergoing PCI (53-55). The JUMBO-TIMI 26 trial was a phase 2 randomized study of 904 
patients designed to assess the safety of prasugrel when administered at the time of PCI and 
the results of this trial showed no difference in the rates of clinically significant bleeding 
events (56). In PRINCIPLE-TIMI 44, 201 subjects were randomized to either prasugrel 60 mg 
or clopidogrel 600 mg as a loading dose one half hour prior to elective PCI, and then to 
either prasugrel 10 mg or clopidogrel 150 mg as a maintenance dose (57). The prasugrel 
groups were found to achieve significantly greater levels of platelet inhibition in both the 
loading and maintenance phases. To assess prasugrel’s clinical efficacy, the landmark 
TRITON-TIMI 38 trial enrolled 13,608 patients with moderate- to high-risk ACS (including 
both NSTE-ACS and STEMI) undergoing PCI and randomly assigned patients to either 
prasugrel (60 mg loading dose followed by 10 mg maintenance dose) or clopidogrel (300 mg 
loading dose followed by 75 mg maintenance dose) (58). At 15 month follow-up, prasugrel 
reduced the composite endpoint of death, nonfatal MI or nonfatal stroke by 20% in 
comparison to clopidogrel (9.9% vs. 12.1%; HR 0.81; 95% CI 0.73-0.90; p<0.001) with the 
majority of the difference driven by lower rates of nonfatal MI (7.4% vs. 9.7%). Stent 
thrombosis was also significantly reduced with prasugrel (1.1% vs. 2.4%; p<0.001), however, 
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the risk for bleeding in all categories was significantly increased including major bleeding 
(2.4% vs. 1.8%; p=0.03), life-threatening bleeding (1.4% vs. 0.9%; p=0.01), and fatal 
hemorrhage (0.4% vs. 0.1%; p=0.002). Risk factors for bleeding included age ≥75 years, 
history of stroke or TIA, and body weight <60 kg. Overall mortality did not differ 
significantly between the treatment groups.   
The 2009 ACC/AHA Joint STEMI/PCI updated guidelines recommend that in patients with 
ACS in whom PCI is planned, a loading dose of either clopidogrel of at least 300 to 600 mg 
(Class I, Level of Evidence C) or prasugrel 60 mg (provided there are no contraindications) 
(Class I, Level of Evidence B) be given as soon as possible. For STEMI patients who have 
received fibrinolytic therapy, clopidogrel at a loading dose of either 300 or 600 mg should be 
given followed by clopidogrel as the thienopyridine of choice for maintenance therapy 
(Class I, Level of Evidence C). The choice and duration of maintenance therapy for ACS 
patients receiving a BMS or DES should be either clopidogrel 75 mg daily (Class I, Level of 
Evidence B) or prasugrel 10 mg daily (provided there are no contraindications) (Class I, 
Level of Evidence B) for at least 12 months unless the risk of morbidity due to bleeding 
outweighs the anticipated benefit of thienopyridine therapy, at which point earlier 
discontinuation should be considered (Class I, Level of Evidence C). In patients in whom 
coronary artery bypass grafting (CABG) is planned and can be delayed, it is recommended 
that clopidogrel be withdrawn for at least 5 days (Class I, Level of Evidence B) and 
prasugrel for at least 7 days (Class I, Level of Evidence C) unless the need for 
revascularization and/or the net benefit of the thienopyridine outweighs the risks of 
bleeding (Class I, Level of Evidence C). Age ≥ 75 years, history of TIA or stroke, and active 
major bleeding are contraindications to prasugrel therapy. Body weight < 60 kg is a relative 
contraindication to prasugrel therapy and consideration of lowering the maintenance dose 
from 10 mg to 5 mg daily should be given, though the safety and efficacy of the 5 mg dose 
have not been established (17).    
2.5 Ticragrelor 
Ticragrelor is an oral antiplatelet agent from the cyclopentyltriazolopyrimidine class that 
reversibly binds the ADP-P2Y12 platelet receptor. Like prasugrel, it is known to produce a 
more rapid and intense reduction in platelet function when compared to clopidogrel.  In the 
PLATO trial, 18,624 patients with ACS (38% STEMI) were randomized to either ticragrelor 
(180 mg loading dose followed by 90 mg twice daily) or clopidogrel (300 to 600 mg loading 
dose followed by 75 mg daily) in addition to chronic aspirin therapy (59). At 12 months, 
ticragrelor therapy was associated with a significant reduction in the primary efficacy 
endpoint of cardiovascular death, MI or stroke (9.8% vs. 11.7%; HR 0.84; 95% CI 0.77-0.92; 
p<0.001). Importantly, the rate of death from any cause was reduced in the ticagrelor group 
(4.5% vs. 5.9% with clopidogrel, p<0.001). Furthermore, there were no significant differences 
in the rates of major bleeding, although ticagrelor was associated with a higher rate of 
bleeding not related to CABG. The STEMI patients in PLATO, when analyzed separately, 
also showed a benefit of ticagrelor over clopidogrel with trends consistent with the overall 
PLATO trial.  In addition, ticagrelor reduced rates of MI alone, total mortality, and stent 
thrombosis.  The reductions in stent thrombosis (ST) for ticagrelor versus clopidogrel were 
1.6% vs. 2.4% (definite ST, p=0.03), 2.6% vs. 3.4% (definite or probable ST), and 3.3% vs. 4.3% 
(definite, probable, or possible ST). A subgroup analysis of patients with chronic kidney 
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disease found that ticragrelor produced a more pronounced reduction in the primary 
endpoint when compared to patients with normal renal function as well as an overall 
decrease in total mortality (60).  
3. Anti-thrombotic agents 
3.1 Unfractionated heparin 
Unfractionated heparin (UFH) inhibits platelet aggregation and fibrin formation by 
accelerating the action of antithrombin, which in turn inactivates factors IIa, IXa, and Xa. 
The evidence for UFH therapy in UA and NSTE-ACS has been well defined in early trials 
such as RISC and ATACS (61-65), however, the benefits in acute STEMI are less clear. 
Current ACC/AHA guidelines on the management of acute STEMI recommend intravenous 
UFH therapy for all patients treated with a fibrin-specific fibrinolytic agent (alteplase, 
tenecteplase, reteplase) or a non-fibrin-specific agent (streptokinase, urokinase, anistreplase) 
if the risk for systemic embolization is high (large or anterior MI, atrial fibrillation, prior 
embolus, or known left ventricular thrombus).  The goal for activated partial thromboplastin 
time (aPTT) should be 1.5 to 2.0 times control or between 50-70 seconds. The benefit of 
adjunctive UFH with fibrinolytic therapy is thought to be due to its effect on maintaining 
infarct vessel patency as there is limited data regarding any improvements in either 
mortality or reinfarction (66-69). In patients being referred for PCI, current guidelines 
recommend intravenous treatment with UFH (17). UFH use during PCI is believed to 
reduce the risk for acute vessel closure as well as catheter or wire thrombosis and has been 
extrapolated from data obtained from PTCA prior to the era of coronary stenting and dual 
anti-platelet therapy (70). The 2005 ACC/AHA/SCAI guidelines for PCI recommend that in 
patients not receiving a glycoprotein (GP) IIb/IIIa inhibitor, UFH should be given using a 
bolus of 70 to 100 IU/kg to target an activated clotting time (ACT) between 250 to 350 
seconds. For patients who are receiving a GP IIb/IIIa inhibitor, heparin bolus should be 
lowered to 50 to 70 IU/kg to achieve an ACT of 200 to 250 seconds (71). Heparin monitoring 
during PCI is generally done with ACT instead of aPTT as the anticoagulation levels 
required during the procedure are frequently too high for aPTT to track.  An alternative 
strategy endorsed by the 2005 European Society of Cardiology guidelines for PCI was a 
single bolus of 100 IU/kg without ACT monitoring (72). The routine use of UFH after 
uncomplicated procedures has not been shown to reduce stent thrombosis and is not 
recommended given its association with increased rates of bleeding and vascular access 
complications.  UFH use can cause autoimmune heparin-induced thrombocytopenia, a rare 
but potentially lethal complication associated with thrombosis. Treatment includes prompt 
withdrawal of UFH or low molecular weight heparin (LMWH) and initiation of alternative 
anticoagulation therapy (argatroban, lepirudin, bivalirudin). 
3.2 Low-Molecular-Weight Heparin 
Low-molecular-weight heparin (LMWH), like UFH, prevents clot propagation, but 
possesses several advantages over UFH due to different mechanisms of action. The ratio of 
anti-Xa/anti-IIa activity is significantly higher in LMWH compared to UFH, thereby 
inhibiting thrombin generation more effectively with potentially less bleeding. Suppression 
of the release of von Willebrand factor also augments LMWH’s anticoagulant effect. 
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Increased bioavailability leads to a longer duration of systemic anticoagulation and less 
binding to plasma proteins and produces a more consistent anticoagulant effect. Several 
trials including FRISC, FRIC, FRAXIS, TIMI 11-B, and ESSENCE have found that treatment 
with LMWH is at least as effective as UFH across a spectrum of ACS patients while 
maintaining a comparable safety profile (73-79). The efficacy and safety of LMWH in PCI as 
compared to UFH was studied in over 10,000 patients with NSTE-ACS being referred for 
early invasive strategy in the SYNERGY trial (80). While enoxaparin use was shown to be 
non-inferior to UFH, it was associated with a significantly higher rate of major bleeding 
(9.1% vs. 7.6%).  STEEPLE, a trial designed to assess the safety of enoxaparin (a single 
intravenous bolus of either 0.50 or 0.75 mg/kg prior to PCI) compared to UFH in over 2,500 
patients undergoing elective PCI was terminated early due to an excess mortality rate 
among the patients receiving lower dose enoxaparin (81). As such, the 2005 
ACC/AHA/SCAI guideline update for PCI recommends UFH as first line antithrombotic 
therapy in patients undergoing PCI except in patients with heparin-induced 
thrombocytopenia (Class I, Level of Evidence C). LMWH is a reasonable alternative in 
patients with UA/NSTEMI (Class IIa, Level of Evidence B) and in patients with STEMI 
(Class IIb, Level of Evidence B) (71).   
3.3 Fondaparinux 
Fondaparinux, a selective inhibitor of factor Xa, was tested against UFH in 350 patients 
undergoing urgent or elective PCI in the ASPIRE pilot trial and was found to have similar 
efficacy and safety outcomes (82). This issue was further examined in the much larger 
OASIS-6 trial, which included over 12,000 STEMI patients split into two strata based on 
whether UFH was indicated or not (83). Stratum 1 in which UFH was not indicated 
consisted of 5,658 patients most of whom had received fibrinolytic therapy with 
streptokinase and in whom adequate reperfusion was achieved and PCI was not planned. 
Stratum 2 consisted of 6,434 patients in whom UFH was indicated (those who received a 
fibrin-specific fibrinolytic agent, those in whom adequate reperfusion was not achieved, or 
those in whom primary PCI was planned). Patients in each stratum were then randomized 
to receive either fondaparinux or placebo. Although there was an overall decrease in the 
primary endpoint of death or reinfarction with fondaparinux (9.7% vs. 11.2%), investigators 
found that this effect was driven mainly by a significant reduction in events in the stratum 
that did not receive heparin or primary PCI and that there was actually a trend towards 
worse outcomes with fondaparinux in the stratum of patients who received heparin and 
were treated with primary PCI. Fondaparinux use was also associated with a higher rate of 
catheter related thrombosis as well as coronary complications during PCI such as acute 
vessel closure, no reflow phenomenon, and dissection. Therefore, the 2007 focused update of 
the ACC/AHA/SCAI guidelines for PCI do not recommend fondaparinux use as the sole 
anticoagulant to support PCI and when used should be supplemented with another agent 
that has anti-IIa activity such as UFH or bivalirudin (84).  
3.4 Direct thrombin inhibitors 
Direct thrombin inhibitors (e.g., hirudin, bivalirudin, lepirudin) inactivate thrombin by 
binding directly to its catalytic site and hold several advantages over UFH in that 
antithrombin is not required as a cofactor allowing clot-bound thrombin to be inactivated 
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(85). Additionally, there is no thrombin-mediated activation of platelets. Hirudin, a 
naturally occurring peptide derived from the saliva of the medicinal leech has been studied 
in patients with ACS undergoing reperfusion therapy with fibrinolytics or PCI (TIMI-9B, 
GUSTO-IIB, HELVETICA) and found to have no benefit when compared to UFH with 
comparable rates of major bleeding (86-88). The pilot trial HERO reproduced a similar 
finding with bivalirudin, a synthetic peptide that directly inhibits free and clot-bound 
thrombin (89). When given concurrently with streptokinase, bivalirudin was more effective 
than UFH in producing early infarct-related artery patency (TIMI grade 3 flow) without 
increasing the risk of major bleeding. The follow up HERO-2 mortality trial found that 
bivalirudin had similar rates of mortality at 30 days (10.5% vs. 10.9% with UFH, OR 0.99) 
with a small reduction in reinfarction at 96 hours (1.6% vs. 2.3%) and a nonsignificant trend 
toward more severe bleeding (0.6% vs. 0.4%) (90). The 2004 AHA/ACC guidelines on the 
management of STEMI state that it is reasonable to consider bivalirudin as an alternative to 
UFH in patients with heparin-induced thrombocytopenia and who are treated with 
streptokinase.  
The role of bivalirudin in primary PCI was evaluated in the HORIZONS-AMI trial in which 
3,602 patients with STEMI undergoing primary PCI were randomized to receive treatment 
with either UFH plus a GP IIb/IIIa inhibitor or to treatment with bivalirudin alone with 
provisional GP IIb/IIIa inhibitor (91). The investigators found that anticoagulation with 
bivalirudin alone resulted in lower rates of MACE at 30 days (9.2% vs. 12.1%; RR 0.76; 95% 
CI 0.63-0.92; p=0.005), major bleeding (4.9% vs. 8.3%; RR 0.60; 95% CI 0.46-0.77; p<0.001), 30-
day death from cardiac causes (1.8% vs. 2.9%; RR 0.62; 95% CI 0.40-0.95; p=0.03), and 30-day 
overall mortality (2.1% vs. 3.1%; RR 0.66; 95% CI 0.44-1.00; p=0.047). There was a concern 
about a significant 1% increase in acute stent thrombosis seen within 24 hours, however, the 
rates for stent thrombosis at 30 days were similar in both groups. Bivalirudin was further 
examined in the REPLACE-2, ISAR-REACT 3, and ACUITY randomized trials evaluating 
patients across a broad spectrum of disease (stable CAD to high-risk ACS) undergoing PCI 
(92-94). The results of these trials solidified bivalirudin’s favorable safety and efficacy profile 
when compared to UFH plus a GP IIb/IIIa inhibitor by demonstrating the non-inferiority of 
bivalirudin in preventing ischemic complications after PCI along with a reduction in rates of 
major bleeding. Additionally, a meta-analysis of randomized trials revealed that bivalirudin 
use provided greater absolute benefits in the prevention of ischemic and bleeding 
complications in patients with renal insufficiency (95). In the 2009 Focused Update of the 
ACC/AHA guidelines for the management of patients with STEMI/PCI, bivalirudin was 
added as an acceptable anticoagulant for primary PCI (Class I, Level of Evidence B) as well 
as in STEMI patients undergoing PCI who are at high risk of bleeding (Class IIa, Level of 
Evidence B) (17).  
3.5 Glycoprotein IIb/IIIa inhibitors 
Glycoprotein (GP) IIb/IIIa is an integrin receptor expressed on the surface membrane of 
platelets that undergoes a conformational change following platelet activation allowing it to 
bind to fibrinogen and cross-link with other platelets. This forms the basis for platelet 
aggregation and the pathologic vascular thrombosis seen in ACS. Three GP IIb/IIIa 
inhibitors are currently approved for use in ACS and PCI although much of the evidence 
supporting their use was established in the era prior to dual oral antiplatelet therapy.  
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Abciximab is the Fab fragment of a human-murine monoclonal antibody directed at the GP 
IIb/IIIa receptor. A number of clinical trials have attempted to evaluate its use in patients 
undergoing PCI for stable angina or ACS. These include EPIC, EPILOG, CAPTURE, 
RAPPORT, ADMIRAL, ISAR-2, ISAR-REACT, ISAR-SWEET, CADILLAC, ACE, EPISTENT, 
and ERASER (96-107). Pooled analyses of several of these trials have found that abciximab 
significantly reduced the incidence of 30-day death and MI when compared to placebo (HR 
0.55; 95% CI 0.43-0.69; p<0.001) (108). This benefit was found regardless of the type of 
coronary intervention used including balloon angioplasty, elective stenting, bail-out 
stenting, and directional atherectomy, without an increase in significant bleeding 
complications. Protection from major adverse outcomes with abciximab continued out to six 
months and was independent of gender and a significant mortality benefit persisted at three 
years (6.4% vs. 5.0%; HR 0.78; 95% CI 0.63-0.98; p=0.03) (109-110). In the BRAVE-3 study, 800 
patients presenting within 24 hours of STEMI were treated with aspirin, clopidogrel 600 mg, 
and randomized to either abciximab or placebo given prior to primary PCI. There were no 
significant differences between the two groups with respect to the primary endpoint of 
infarct size as measured by single-photon emission computed tomography (SPECT) or in 30 
day MACE (111).         
Tirofiban is a non-peptide molecule that exhibits dose dependent inhibition of the GP 
IIb/IIIa receptor. The RESTORE trial randomized 2,139 patients with ACS undergoing 
PTCA with balloon angioplasty or directional atherectomy to either placebo or tirofiban (10 
μg/kg/3 min intravenous bolus followed by continuous infusion of 0.15 μg/kg/min for 36 
hours) (112). The composite end point (death from any cause, MI, bypass surgery for 
angioplasty failure or recurrent ischemia necessitating repeat PCI) was reduced by tirofiban 
at two days (RR 38%; p<0.005) and at seven days (RR 27%; p=0.022) post-PTCA however 
this reduction was no longer statistically significant at 30 days (10.3% vs. 12.2%; p=0.16) and 
at 6 month follow up (113). The ADVANCE trial then evaluated whether higher doses of 
tirofiban would confer a benefit in 202 patients with ACS undergoing primary PCI (114). 
Patients were randomly assigned to either placebo or tirofiban (25 μg/kg/3 min bolus plus 
0.15 μg/kg/min continuous infusion for 24 to 48 hours). The results of this study showed 
that treatment with high dose tirofiban produced a significant reduction in the primary 
endpoint of death, MI, target vessel revascularization, or bailout use of a GP IIb/IIIa 
inhibitor (35% vs. 20%; HR 0.51; 95% CI 0.29-0.88; p=0.01). The difference was driven by a 
reduction in MI and bailout use of GP IIb/IIIa inhibitors with no significant effect on 
mortality. Bleeding rates were comparable between tirofiban and placebo. Subgroup 
analyses found that while patients with ACS benefited from tirofiban use, those with stable 
angina did not. Diabetics also appeared to gain a benefit with tirofiban while nondiabetics 
did not. Upstream use of tirofiban prior to PCI in patients with STEMI was evaluated in 
three trials: TIGER-PA, ON-TIME, and ON-TIME 2 (115-117). These trials demonstrated that 
tirofiban use was generally associated with improved electrocardiographic endpoints such 
as resolution of ST-segment elevations with no increase in the risk of major or minor 
bleeding. In the ON-TIME 2 trial, approximately 1,000 patients with STEMI were 
randomized to pre-treatment with either high dose tirofiban or placebo prior to PCI and 
while there was an improvement in ST-segment resolution in the tirofiban group, there was 
no significant difference between the two groups in angiographic variables such as 
Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow or blush grade. Later results 
from ON-TIME 2 however reported a significant reduction in 30 day MACE in the tirofiban 
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group (5.8% vs. 8.6%; p=0.043) that was maintained at 1-year follow up (3.7% vs. 5.8%; 
p=0.08) (118).   
Eptifibatide is a synthetic, nonimmunogenic cyclic heptapeptide inhibitor of GP IIb/IIIa 
with an active pharmacophore which is derived from the structure of barbourin, a GP 
IIb/IIIa inhibitor isolated from the venom of the Southeastern pigmy rattlesnake (119). It has 
a rapid onset of action with a plasma half-life of 10-15 minutes making its antiplatelet effect 
rapidly reversible. Its use in ACS and PCI has been evaluated in several clinical trials. In the 
PURSUIT trial, 10,948 patients were randomized to eptifibatide or placebo in conjunction 
with UFH and aspirin (120). By four days, the combined endpoint of death and nonfatal MI 
were reduced by 1.5% in the eptifibatide group (14.2% vs. 15.7%; p=0.04). More remarkably, 
this benefit was apparent as early as 96 hours and persisted through 30 days with a greater 
benefit observed in patients undergoing early angioplasty (121). In the IMPACT-II trial of 
4,010 patients undergoing elective, urgent or emergent PCI, treatment with eptifibatide 
during PCI reduced the rates of early abrupt vessel closure and ischemic events by 30 days 
(122). The benefits of eptifibatide have also been shown in patients undergoing elective PCI, 
as seen in the ESPRIT trial that randomized 2,064 patients to pre-treatment with placebo or 
ebtifibatide prior to PCI (123). The trial was terminated early for efficacy as pre-treatment 
with ebtifibatide led to a significant reduction in the primary end point of death, MI, urgent 
revascularization, or need for bail-out GP IIb/IIIa inhibitor at 48 hours (6.6% vs. 10.5%; 
p=0.0015) as well as at 30 days (6.8% vs. 10.5%; p=0.0034). With regards to safety endpoints, 
bleeding rates with eptifibatide were equivalent to placebo in IMPACT-II (4.8% vs. 5.1%), 
although severe bleeding without hemorrhagic stroke was increased in PURSUIT (11.6% vs. 
9.2%) (104, 106). Additionally, a pooled analysis of eight randomized control trials showed 
that eptifibatide did not significantly increase the rate of thrombocytopenia compared to 
placebo (124).       
The general benefits of intravenous GP IIb/IIIa inhibitors have been evaluated in a meta-
analysis pooling data from 21 trials involving patients with a broad range of CAD (125). The 
study reported that GP IIb/IIIa inhibitor use produced significant reductions in the 
combined end point of 30-day death, MI, or urgent revascularization in patients undergoing 
PCI (7.8% vs. 11.6%), patients with NSTE-ACS (11.4% vs. 12.8%), and patients with acute 
STEMI who underwent angioplasty (3.9% vs. 7.8%). The benefits of adjunctive GP IIb/IIIa 
inhibitors in acute STEMI remain uncertain however. As discussed in the section on 
bivalirudin, the HORIZONS-AMI trial randomized 3,602 patients with STEMI undergoing 
primary PCI to UFH with a GP IIb/IIIa inhibitor (either abciximab or eptifibatide) or to 
bivalirudin alone with provisional GP IIb/IIIa (91). All patients were treated with aspirin 
and a thienopyridine prior to PCI. Of the 1,661 patients who were randomized to treatment 
with UFH, 757 received a double bolus of eptifibatide and 863 received abciximab. In the 
bivalirudin alone plus provisional GP IIb/IIIa arm, only 53 of 1,674 patients received 
eptifibatide and 72 received abciximab. At 30 days, the primary endpoint of MACE as well 
as major bleeding was higher in the group that received UFH and a GP IIb/IIIa inhibitor as 
compared to bivalirudin alone. A subgroup analysis of the UFH plus GP IIb/IIIa group 
compared those treated with eptifibatide and abciximab and found that there was no 
significant difference in the incidence of stent thrombosis at one year (126). 
With regards to the timing of adjunctive GP IIb/IIIa use in patients undergoing PCI for 
acute STEMI, a meta-analysis of six randomized trials including TIGER-PA and ON-TIME 
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found that early administration (prior to transfer to catheterization laboratory) as compared 
to late (at the time of PCI) improved measures of coronary patency as well as clinical 
outcomes (127). The FINESSE trial also addressed the issue of timing of GP IIb/IIIa inhibitor 
therapy. In the trial, 2,453 patients with STEMI were randomized to pre-PCI treatment with 
a half-dose fibrinolytic agent plust abciximab, pre-PCI abciximab alone, or abciximab at the 
time of PCI (128). The primary endpoint was composite death, ventricular fibrillation 
occurring over 48 hours after randomization, cardiogenic shock and congestive heart failure 
during the first 90 days after randomization. The results of this trial showed no benefit and 
perhaps a trend towards more bleeding with abciximab pre-treatment as compared to 
abciximab given at the time of PCI.  
With regards to its safety profile, there does appear to be an increased risk of bleeding with 
the use of intravenous GP IIb/IIIa inhibitors, however a pooled analysis of 14 randomized 
trials including approximately 28,000 patients found no difference in the incidence of 
intracerebral hemorrhage when comparing heparin plus any GP IIb/IIIa inhibitor to heparin 
plus placebo (0.12% vs. 0.09%, OR 1.3), or when comparing a GP IIb/IIIa inhibitor alone 
with heparin alone (129).  
When deciding between agents for use in PCI, it is unclear whether one GP IIb/IIIa inhibitor 
holds any significant advantage in clinical efficacy over another. It is likely that the level of 
platelet inhibition achieved at two hours is similar between all three agents although there is 
some suggestion that the current recommended dosing regimen for tirofiban produces 
relatively less platelet inhibition in the first 15 to 60 minutes after coronary intervention 
(130). One of the few clinical trials to compare the clinical efficacy of two GP IIb/IIIa 
inhibitors head to head was the TARGET trial in which 4,809 patients undergoing elective 
PCI were randomly assigned to either abciximab or tirofiban (131). The study showed that 
abciximab (0.25 mg/kg bolus followed by 0.125 µg/kg [maximum 10 µg/min] for 12 hours) 
was significantly superior to tirofiban (10 µg/kg bolus followed by 0.15 µg/kg for 18 to 24 
hours) in reducing the composite end point of death, MI, or urgent revascularization at 30 
days (6% vs. 7.6%; HR 0.79). The difference appeared to be driven mainly by less procedure 
related MIs in the abciximab group (5.4% vs. 6.9%). A subgroup analysis found that this 
benefit was limited to patients who had ACS or were non-diabetic. At six months however, 
there was no longer any difference in the primary composite endpoint between the two 
drugs and by one year, the benefit of abciximab in the subgroup of patients with ACS had 
disappeared (132-133). A higher tirofiban bolus dose regimen (25 µg/kg bolus over three 
minutes followed by 0.15 µg/kg/min for 18 hours) given prior to PCI is being compared 
with pre-treatment with abciximab in the ongoing TENACITY trial.  MULTISTRATEGY was 
an open-label, multi-center European trial which randomized 745 patients with STEMI 
undergoing primary PCI in a 2-by-2 factorial design to pre-treatment with either high dose 
tirofiban or abciximab and sirolimus-eluting stent versus bare-metal stent (134). All patients 
received dual oral anti-platelet therapy with aspirin and clopidogrel as well as with UFH. 
There was no significant difference between the GP IIb/IIIa groups in the primary end 
points of ST-segment resolution at 90 minutes after PCI (RR 1.020; 97.5% CI 0.958-1.086; 
p=0.001 for non-inferiority) and the rate of MACE at 8 months. Rates of major and minor 
bleeding complications were similar, however the incidence of moderate or severe 
thrombocytopenia was increased with abciximab (4.0% vs. 0.8%; p=0.004). To date 
abciximab has not been directly compared to ebtifibatide to evaluate relative clinical 
efficacy, although one study showed that compared to tirofiban, ebtifibatide was as effective 
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as abciximab in achieving a greater proportion of patients in whom there was greater than 
80% inhibition of platelet activation at 15 minutes (135). A retrospective analysis of 452 
patients with STEMI undergoing primary PCI who received adjunctive therapy with either 
abciximab or eptifibatide found no significant differences in clinical outcomes including 
reinfarction (2% vs. 3% for eptifibatide and abciximab respectively), repeat revascularization 
(3% vs. 4%), bleeding complications (8% vs. 12%), congestive heart failure (5% vs. 3%), 
cerebrovascular accidents (0% vs. 2%), renal failure (2% vs. 3%), and all-cause mortality at 
discharge (5% vs. 4%) as well as at 6 months (6.5% vs. 6.4%; HR 0.976; 95% CI 0.43-2.23; log-
rank, p=0.95) (136).  
Given the above evidence, the 2009 ACC/AHA Focused Updates of the STEMI and PCI 
guidelines concluded that in the setting of dual antiplatelet therapy with aspirin and a 
thienopyridine plus either UFH or bivalirudin as the anticoagulant, GP IIb/IIIa inhibitors 
can be useful at the time of primary PCI but cannot be recommended as routine therapy. In 
select cases such as for the patient with a large thrombus burden or for patients who have 
not received adequate thienopyridine loading, adjunctive treatment with a GP IIb/IIIa 
inhibitor (abciximab [Level of Evidence A], tirofiban [Level of Evidence B], or eptifibatide 
[Level of Evidence B]) may be of more benefit (Class IIa) (17).   
3.6 Fibrinolytic therapy 
Fibrinolytic therapy restores blood flow in the infarct-related artery and has been shown to 
improve mortality in STEMI patients who are not able to receive timely PCI, though not in 
patients with NSTE-ACS. The mortality benefit of fibrinolytic therapy was first 
demonstrated with streptokinase in the GISSI-2 and ISIS-2 landmark trials (137-141). 
Streptokinase is a single chain polypeptide derived from beta-hemolytic streptococcus that 
binds to and cleaves peptide bonds on plasminogen causing an indirect conformational 
change that then activates plasmin. Streptokinase is antigenic and can infrequently cause an 
immunologic sensitization and allergic reaction with repeated use exposure. Increased doses 
are required to neutralize the body’s anti-streptococcal antibodies.  
Alteplase (recombinant tissue-type plasminogen activator, t-PA) is a serine protease that is 
naturally produced by endothelial cells and possesses no antigenic features. In contrast to 
streptokinase (nonfibrin-specific), t-PA is one of several fibrin-specific agents whose ability 
to convert plasminogen to plasmin is greatly enhanced after binding preferentially to fibrin 
in a thrombus with resultant local fibrinolysis. The results of the clinical trial GUSTO-I 
comparing streptokinase and t-PA in 41,000 patients with STEMI demonstrated an absolute 
survival benefit of 1% with t-PA at 30 days (6.3% vs. 7.3%) that persisted at one year (9.1% 
vs. 10.1%) with the most benefit seen in patients less than 75 years old and in those with 
anterior wall infarctions (142-143). Streptokinase however remains the most widely used 
fibrinolytic agent worldwide. Although it is less efficacious than alteplase, it maintains a 
reasonable efficacy to safety ratio with a lower risk of intra-cranial hemorrhage and is 
significantly less expensive.  
Two other genetically engineered fibrin-specific agents currently approved in the US for use 
in the treatment of acute STEMI include reteplase (r-PA) and tenecteplase (TNK). Like t-PA, 
these agents are not antigenic and have no associated risk of allergic reaction.  r-PA is a 
recombinant nonglycosylated form of human tissue plasminogen activator. In comparison 
www.intechopen.com
 
Coronary Interventions 
 
226 
to t-PA, r-PA has a longer half-life and binds fibrin with lower affinity improving its ability 
to penetrate into clots, though clinical trials (RAPID I and II, GUSTO III, INJECT) have 
generally demonstrated similar outcomes with r-PA and t-PA (144-148). The newest of 
these, tenecteplase (TNK) is a recombinant plasminogen activator derived from the native t-
PA. It possesses 14 times more specificity to fibrin and is 80 times more resistant to 
inhibition by plasminogen activator inhibitor 1 (PAI-1) (149). It has a longer plasma half-
life, allowing for easier and faster treatment with a single intravenous bolus injection and 
has been shown in several clinical trials including TIMI 10A and 10B, ASSENT-1 and 
ASSENT-2 to be as effective as t-PA with a significant reduction in non-cerebral bleeding 
(150-153). 
Lanoteplase (n-PA) is another genetically engineered mutant of wild-type t-PA, however, it 
is not currently approved for use due to an increase in hemorrhagic stroke (154-155). 
Anistreplase (APSAC) is another fibrinolytic agent that has a significantly longer half-life 
compared to streptokinase (90 to 100 minutes versus 18-23 minutes). Like streptokinase and 
staphylokinase, it is antigenic leading to restrictions in repeated use. Though its efficacy and 
safety profiles were similar to streptokinase, anistreplase is no longer available. Urokinase is 
a non-fibrin specific fibrinolytic and is a nonselective activator of plasminogen. Urokinase is 
currently used only in the treatment of pulmonary embolism.       
Absolute contraindications to fibrinolytic therapy include any history of intracranial 
hemorrhage, history of ischemic stroke within the preceding three months, presence of a 
cerebral vascular malformation or a primary or metastatic intracranial malignancy, 
symptoms or signs suggestive of an aortic dissection, a bleeding diathesis or active bleeding 
with the exception of menses, and a significant closed-head trauma within the preceding 
three months (156). Furthermore, combination therapy with fibrinolytic agents and GP 
IIb/IIIa inhibitors is not recommended owing to a lack of mortality benefit with significantly 
higher rates of bleeding seen in the GUSTO V and ASSENT-3 trials (157-162). 
In patients with acute STEMI, PCI has been shown to be more effective than fibrinolytic 
therapy in preventing death, reinfarction, and stroke (163). However, many patients are 
unable to receive prompt PCI, particularly those who first present to a hospital without PCI 
capabilities. In such cases, it is recommended that patients who are eligible receive early 
fibrinolytic therapy. The issue of whether and when to perform coronary angiography and 
PCI in patients who have received fibrinolytic therapy is complex and has been examined 
extensively in clinical trials.  Evidence suggests that patients who are able to attain 
normalization of blood flow (TIMI grade 3) in the infarct-related artery after fibrinolysis 
tend to have the most favorable outcomes (164-165). Although fibrinolytic therapy restores 
patency (TIMI grade 2 or 3) in 80% of infarct-related arteries, it only restores normalization 
of flow (TIMI grade 3) in 50-60% of arteries. This provides the rationale for performing PCI 
following the administration of fibrinolytic therapy. Two trials, GRACIA-2 and FAST-MI, 
have demonstrated equivalency in efficacy and safety when comparing fibrinolytic therapy 
followed by PCI to primary PCI (166-167). Previously used terms describing specific 
reperfusion strategies with PCI after fibrinolytic therapy have included facilitated PCI and 
rescue PCI, however, the 2009 STEMI/PCI Focused Update considered these labels 
potentially misleading. Though these terms are no longer used in the recommendations, 
many of the previous supporting trials refer to these strategies so a brief review will be 
necessary.  
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Facilitated PCI involves initial treatment with full or half dose fibrinolytic agent or a 
combination of fibrinolytic and GP IIb/IIIa agents followed by immediate PCI. Two large, 
randomized clinical trials have addressed this issue. The trial ASSENT-4-PCI was intended 
to randomize 4,000 patients with STEMI who presented within 6 hours of symptom onset to 
full-dose tenecteplase or placebo prior to primary PCI (168). The trial was terminated early 
due to a significant increase in the primary endpoint of death, heart failure, or shock within 
90 days in the tenecteplase group (19% vs. 13%, RR 1.39, 95% CI 1.11-1.74), along with 
increased mortality (6% vs. 3%), in-hospital stroke (1.8% vs. 0%; mostly intra-cranial 
hemorrhage), as well as reinfarction (6% vs. 4%) and target vessel revascularization (7% vs. 
3%) at 90 days. The FINESSE trial, described in more detail in the GP IIb/IIIa section, 
showed that there was no benefit in the treatment of acute STEMI with half-dose reteplase 
and abciximab prior to PCI with trends toward an increase in intra-cranial hemorrhage as 
well as major and minor bleeding (128). One possible explanation for the poor outcomes 
seen with facilitated PCI is the immediate nature of planned PCI after fibrionlytic therapy 
(median time period of 104 minutes between tenecteplase and PCI in the ASSENT-4- PCI 
trial). Recanalization of the infarct artery occurs 30-45 minutes after tenecteplase injection, so 
the relatively short time gain from the point of recanalization until PCI likely exposes the 
patient to more bleeding risk associated with full-dose fibrinolytic and antithrombotic 
therapy relative to any potential smaller benefit of PCI. A subgroup analysis showing a 
trend toward better outcomes when tenecteplase was given in the ambulance compared to 
much worse outcomes when given at a PCI center is consistent with this theory. The results 
of these and various smaller trials, as well as a 2006 meta-analysis have led most major 
society guidelines to recommend against facilitated PCI with full dose fibrinolytic therapy, 
though the 2007 PCI Focused Update makes a weak recommendation for the consideration 
of facilitated PCI using regimens other than full-dose fibrinolytic therapy in patients with 
high-risk STEMI in whom bleeding risk is low and PCI is not immediately available within 
90 minutes (Class IIb, Level of Evidence: C) (84).  
Rescue PCI refers to the strategy of performing PCI only if there are clinical or 
electrocardiographic signs of failed reperfusion of the infarct artery after treatment with 
fibrinolytics. The 2007 PCI Focused Update makes a Class I recommendation for rescue PCI 
or emergency CABG for cardiogenic shock in patients less than 75 years of age (Level of 
Evidence: B), severe congestive heart failure and/or pulmonary edema (Killip class III) 
(Level of Evidence: B), or hemodynamically compromising ventricular arrhythmias (Level 
of Evidence: C). Rescue PCI is also reasonable for cardiogenic shock in patients 75 years of 
age or older if they are suitable candidates for revascularization (Level of Evidence: B), 
hemodynamic or electrical instability (Level of Evidence: C), persistent ischemic symptoms 
(Level of Evidence: C), or for <50% ST-segment resolution in the lead that showed the 
greatest degree of ST elevation at presentation at 90 minutes after initiation of fibrinolytic 
therapy and a moderate or large area of myocardium at risk (anterior MI, inferior MI with 
right ventricular involvement or precordial ST-segment depression) (Level of Evidence: B) 
(Class IIa). These recommendations were based largely on results from the REACT trial as 
well as a subsequent meta-analysis of 8 rescue PCI trials demonstrating a clear benefit of 
rescue PCI over repeated doses of fibrinolytic therapy or medical management for failed 
fibrinolysis (169-172). 
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As stated above, the 2009 STEMI/PCI Focused Update has abandoned the potentially 
confusing terms facilitated PCI (immediate planned PCI usually performed within 2 hours 
of fibrinolytic or fibrinolytic plus GP IIb/IIIa therapy) and rescue PCI (PCI reserved for only 
those who fail fibrinolysis) in favor of a pharmacoinvasive strategy (17). Several trials have 
provided valuable evidence informing the 2009 STEMI/PCI Focused Update on this matter. 
In the CARESS-in-AMI trial, 600 STEMI patients 75 years of age or younger with one or 
more high-risk features (extensive ST-segment elevation, new left bundle branch block, 
previous MI, Killip class >2, or left ventricular ejection fraction ≥35%) were treated with 
half-dose reteplase, abciximab, heparin, and aspirin, and randomly assigned to immediate 
transfer for PCI or to standard medical management at the local hospital with transfer only 
for rescue PCI (173). The primary outcome was a composite of death, reinfarction, or 
refractory ischemia at 30 days. PCI was performed in 85.6% of the patients assigned to 
immediate transfer for PCI and rescue PCI was performed in 30.3% of the standard 
care/rescue PCI group. The primary outcome occurred significantly less in the immediate 
PCI group compared to standard care/rescue PCI (4.4% vs. 10.7%; HR 0.40; 95% CI 0.21-0.76; 
log rank p=0.004). There was no difference in major bleeding or strokes between the two 
groups. In the TRANSFER-AMI trial, 1,059 high-risk STEMI patients who were treated with 
tenecteplase within two hours of symptom onset were then randomized to either immediate 
transfer for cardiac catheterization (PCI within 6 hours) or to standard medical care (174). 
High-risk STEMI was defined as ST segment elevation ≥2 mm in two anterior leads or ST-
segment elevation ≥1 mm in two inferior leads plus one or more of the following: systolic 
blood pressure <100 mmHg, heart rate >100 beats/min, Killip class II or III, ST-segment 
depression ≥2 mm in the anterior leads, or ST-segment ≥1 mm in right sided lead (V4R). 
Standard care included rescue PCI if required, or delayed angiography >24 hours after 
STEMI. All patients received aspirin, tenecteplase, and heparin or enoxaparin with a 
recommendation for clopidogrel. The primary endpoint was the composite of death,  
reinfarction, recurrent ischemia, new or worsening congestive heart failure, or cardiogenic 
shock within 30 days. Cardiac catheterization PCI were performed in 98.5% and 84.9% of the 
patients assigned to early PCI at a median of 2.8 hours after randomization and in 88.7% and 
67.4% of the patients assigned to standard treatment at a median of 32.5 hours after 
randomization. At 30 days, the primary endpoint was significantly reduced in the early PCI 
group (11.0% vs. 17.2%; RR 0.64; 95% CI 0.47-0.87; p=0.004) with no significant differences 
between the groups in the incidence of major bleeding. Several other trials have evaluated 
the timing of PCI after fibrinolysis with an early pharmacoinvasive therapy compared to 
standard care including GRACIA-1, NORDISTEMI, and SIAM III (175-177). Each had a 
different study design and thus examined slightly different patient populations but all have 
confirmed the observations seen in CARESS-in-AMI and TRANSFER-AMI that a 
pharmacoinvasive strategy with immediate or early PCI after fibrinolytic therapy (within 3 
to 24 hours) produces better outcomes than standard medical care with rescue PCI or 
routine late PCI (over 24 hours).  
Based on the above evidence, a pharmacoinvasive approach to the management of STEMI 
patients who present to a hospital without PCI capabilities has been developed, which 
includes routine use of a pharmacologic agent (either fibrinolytic therapy or a GP IIb/IIIa 
inhibitor) prior to transfer to a PCI-capable hospital for diagnostic angiogram and 
consideration of PCI (17).  Patients with STEMI who present to a PCI capable hospital are 
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not recommended to receive fibrinolytic therapy and should undergo prompt PCI no later 
than 90 minutes after presentation. STEMI patients who present to a hospital without PCI 
capability should be triaged to either immediate transfer for PCI or to receive fibrinolytic 
therapy if deemed an appropriate candidate. Those with high-risk STEMI features 
(congestive heart failure, cardiogenic shock, electrical instability, etc.), elevated bleeding risk 
with fibrinolytic therapy, or presenting more than 4 hours after symptom onset may be 
better suited for immediate transfer for PCI without delay for fibrinolytic therapy if the time 
required for transport to the receiving hospital is not prolonged. STEMI patients who 
present early after symptom onset with low bleeding risk are the most suitable candidates 
for fibrinolytic therapy. If after receiving the fibrinolytic agent the patient is deemed to have 
high-risk features, the patient should then be immediately transferred for PCI with the 
intention to perform diagnostic catheterization with possible PCI within 3 to 24 hours of 
presentation. Patients who are not judged to be high-risk may be transferred to a PCI-
capable hospital after receiving antithrombotic therapy or may be observed in the initial 
facility.  
3.7 Platelet function testing (P2Y12 testing) 
Several studies have shown that patients with high platelet reactivity despite being treated 
with clopidogrel have a higher incidence of cardiovascular events after PCI (178). This has 
led to a departure from the “one size fits all” paradigm in clopidogrel use during PCI as 
well as investigations into the different genetic and clinical factors that affect individual 
response in platelet reactivity.  Clopidogrel is a prodrug which requires biotransformation 
to its active thiol metabolite via the hepatic cytochrome P450 system (179). It exerts its 
antiplatelet effect by irreversibly binding the adenosine diphosphate receptor P2Y12, a G-
protein coupled receptor found on the platelet surface, which mediates inhibition of 
adenylyl cyclase resulting in the final activation of the GPIIb/IIIa receptor (180). Blockade of 
this pathway with clopidogrel inhibits platelet aggregation and along with the co-
administration of aspirin has contributed to a substantial reduction in thrombotic 
complications peri-PCI (181). Pharmacokinetic and pharmacodynamic data have revealed 
significant inter-individual variability in platelet response to clopidogrel, with reports of 
clopidogrel “non-responsiveness” in up to 30% of Caucasian patients (182-183). There are 
many potential causes of clopidogrel response variability with recent studies focusing on 
genetic variations in hepatic CYP isoenzymes, in particular single-nucleotide 
polymorphisms of CYP2C19.  In a genetic substudy from the TRITON-TIMI 38 trial, patients 
with a reduced function CYP2C19 allele who were treated with clopidogrel had lower 
serum levels of active clopidogrel metabolite as well as diminished platelet inhibition 
leading to higher rates of major adverse cardiovascular events including stent thrombosis 
when compared to noncarriers of the CYP2C19 allele (12.1% vs. 8.0%; HR 1.53; 95% CI 1.07 
to 2.19; p = 0.01) (184). Additionally, variants in ABCB1, a gene encoding for efflux pump P-
glycoprotein expressed on intestinal epithelial cells, have been reported to affect clopidogrel 
absorption and efficacy. Carriers of the specific ABCB1 polymorphism 3435CT, 
particularly those who are TT homozygotes have lower serum levels of active metabolite 
when treated with clopidogrel as well as higher rates of a combined endpoint of 
cardiovascular death, myocardial infarction, or stroke (12.9% vs. 7.8%; HR 1.72; 95% CI 
1.22–2.44; p=0.002) (185). Further studies are needed to determine how much a role 
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ABCB1 variants play in clopidogrel response variability. Genome-wide association studies 
have shown that the heritability of platelet response to clopidogrel may be as high as 70%, 
with the reduced function CYP2C19*2 polymorphism accounting for only 12% of the 
clopidogrel response variability (186). As such, much of the inter-individual variability 
cannot be explained by genotype differences alone.  Given the complexity of testing for 
multiple genetic polymorphisms along with its as yet uncertain yield, there has been 
increasing interest recently in the direct assessment of platelet reactivity peri-
procedurally.   
A number of different methods exist for the laboratory quantification of platelet inhibition. 
Light transmittance aggregometry (LTA) analyzes percent inhibition by measuring the 
amount of transmitted light through a vial of platelet plasma before and after the addition of 
ADP, which induces platelet aggregation.  LTA is considered the “gold standard” for 
measurement of platelet aggregation but the test is very labor intensive and thus limits its 
routine use for guiding clinical care. Other tests for platelet inhibition include flow 
cytometry, platelet function analyzer (PFA-100), vasodilator-stimulated phosphoprotein 
(VASP) phosphorylation assay, and the bedside VerifyNow P2Y12 assay, which measures 
the aggregation of platelets to fibrinogen-coated beads. A study by Price et al. reported that 
the optimal cut-off value for post-PCI platelet reactivity as measured by the VerifyNow 
P2Y12 assay is 235 PRU (P2Y12 reactivity units) (187). Patients with increased residual 
platelet reactivity (measured at ≥235 PRU) after PCI had significantly higher rates of 
cardiovascular death (2.8% vs 0%, p=0.04), stent thrombosis (4.6% vs 0%, p=0.004), and the 
combined ischemic endpoints (6.5% vs 1.0%, p=0.008) at 6 months. Due to its high predictive 
value for post-PCI outcomes and its ease of use as a point-of-care platelet function assay, the 
use of VerifyNow P2Y12 assay as a clinical guide for intensified platelet inhibition therapy 
was recently evaluated in the large multi-center trial, GRAVITAS (188). Investigators in the 
GRAVITAS trial randomized patients with stable CAD or NSTE-ACS and high on-treatment 
platelet reactivity as defined by a PRU value of ≥230 after PCI to treatment with either high-
dose clopidogrel (first-day loading dose of 600mg, followed by 150mg daily for 6 months) or 
standard-dose clopidogrel (required to have received either 300mg loading dose at the time 
of PCI or at least 75mg daily for seven days preceding PCI and standard maintanence 75mg 
dose for 6 months).  The results of the trial failed to demonstrate a reduction in the incidence 
of cardiovascular death, non-fatal MI, or stent thrombosis with the use of high-dose 
clopidogrel (2.3% vs 2.3%; HR 1.01; 95% CI 0.58-1.76; p=0.97) (11).  A second trial, 
TRIGGER—PCI, intended to compare the use of clopidogrel versus prasugrel in patients 
undergoing stenting for stable CAD with high post-PCI residual platelet reactivity (defined 
as a PRU>208 utilizing the VerifyNow P2Y12 assay).  Unfortunately, the trial was 
terminated early due to an unexpected low rate of primary endpoint events in both groups, 
reported to be even less than the low event rates seen in the GRAVITAS trial. It has been 
hypothesized that these two trials were negative mainly because the patient population 
studied was at low risk for cardiovascular complications – patients with stable CAD 
undergoing successful uncomplicated PCI with contemporary drug-eluting stents.  Based on 
the results of these two trials, it may be argued that platelet function testing in these low-
risk situations has limited value as there is little to be gained from more potent platelet 
inhibition.  Whether a personalized approach to intensified platelet inhibition therapy can 
be beneficial in higher risk groups such as patients with acute coronary syndromes, patients 
www.intechopen.com
 
Pharmacotherapy During Percutaneous Coronary Interventions 
 
231 
with diabetes, patients with complex coronary anatomy and complex interventions as well 
as clopidogrel “hypo-responsiveness” remains to be determined and requires further 
prospective investigation.      
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